The clinical pharmacology of the anticancer polypeptide neocarzinostatin was studied in 16 patients with disseminated neoplasia using a radioimmunoassay technique. Patients who received 2,400–3,600 U of the drug per square meter BSA by rapid IV infusion had triphasic plasma decay curves. For eight patients with normal hepatic and renal function, neocarzinostatin mean plasma half-lives were 0.14, 0.50, and 7.7h. The mean plasma drug clearance was 32.4 ml/min/m2 and the apparent volume of distribution 19.3l/m2. Two patients with liver dysfunction had shorter terminal plasma half-lives and greater drug clearances, while two with renal disease exhibited prolonged plasma half-lives and reduced drug clearances. The mean cumulative urinary excretion of neocarzinostatin was 69.1% of the administered dose at 72 h in three patients with normal hepatic and renal function. One patient with liver disease excreted 90.4%, while a patient with renal disease excreted only 58.1% of the dose in 24 h. In one patient with marked liver disease, biliary excretion accounted for 0.1% of the administered dose in 72 h. Cerebrospinal fluid concentrations of neocarzinostatin studied in two patients showed a CSF penetration of about 16% the plasma concentration at 1–5 h; concentrations persisted for 19 h in one patient with an Omayha reservoir. Neocarzinostatin was rapidly cleared from the plasma and eliminated in the urine. Dosage reductions of 50% are recommended for patients with impaired renal function, while no reduction or escalated doses could be tolerated by patients with liver disease. The pharmacologic data suggest a continuous IV infusion may be a more toxic but perhaps more effective schedule of administration.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bhuyan BK, Scheidt LG, Fraser TJ (1972) Cell cycle specificity of antitumor agents. Cancer Res 32:398–407
Broughton A, Strong JE (1976) Radioimmunoassay of bleomycin. Cancer Res 36:1418–1421
Comis RL, Griffin T, Raso V, Ginsberg S (1977) The clinical pharmacology of Neocarzinostatin. Proc Am Assoc Cancer Res 18:124
Griffin TW, Lister TA, Rybak ME, Rosenthal DS, Canellos G, Woodruff R, Oliver KT (1978) Neocarzinostatin (NCS) in patients with acute non-lymphocytic leukemia (ANLL) in relapse. Proc Am Soc Clin Oncol 19:398
Hall SW, Valdivieso M, Benjamin RS (1977) Clinical pharmacology of bleomycin by radioimmunoassay. Clin Res 25:407A
Hiraki K, Kamimura P, Takahashi I, Nagao T et al. (1973) Neocarzinostatin. A new chemotherapeutic approach to acute leukemia. Nouv Rev Fr Hematol 13:445–452
Ishida N, Miyazaki K, Kumagai K, Kikimaru (1965) Neocarzinostatin, and antitumor antibiotic of high molecular weight. J Antibiot (Tokyo) [A] 18:63–76
Kawai Y, Katoh A (1972) Differential inhibition of DNA and RNA synthesis by neocarzinostatin in cultured Burkitt lymphoma cells. JNCI 48:1535–1538
Kramer WG, Feldman S, Broughton A, Strong JE, Hall SW, Holoye PY (1978) The pharmacokinetics of bleomycin in man. J Clin Pharmacol 18:346–352
Kumagi K, Koide T, Kikuchi M, Ishida N (1970) Specific inhibition of the initiation of DNA synthesis in HeLa cells by neocarzinostatin. Int Cancer Congr Abstr 10:401
Lowenthal I, Parker LM (1977) In vivo distribution of I125 neocarzinostatin (NCS) in tumor-bearing animals. Proc Am Assoc Cancer Res 18:124
Maeda H, Kumagi K, Ishida N (1966) Characterization of neocarzinostatin. J Antibiot (Tokyo) [A] 19:253–259
McKelvey EM, Burgess MA, McCredie KB, Bodey GP (1978) Neocarzinostatin: A phase I clinical trial. Proc Am Assoc Cancer Res 19:186
Ono, Y, Wataube Y, Ishida N (1966) Mode of action of neocarzinostatin: Inhibition of DNA synthesis and degradation of DNA in Sarcina lutea. Biochim Biophys Acta 119:46–58
Sakamoto K, Endo N, Sakka M (1973) Effect of neocarzinostatin on V-79 Chinese hamster cells in vitro. Eur J Cancer 9:725–728
Samy RS, Raso V (1980) Radioimmunoassay of neocarzinostatin, an antitumor protein. Cancer Res 36:4378–4381
Tobey RA (1972) A simple rapid technique for determination of the effects of chemotherapeutic agents on mammalian cell cycle traverse. Cancer Res 309–315
About this article
Cite this article
Hall, S.W., Knight, J., Broughton, A. et al. Clinical pharmacology of the anticancer polypeptide neocarzinostatin. Cancer Chemother. Pharmacol. 10, 200–204 (1983). https://doi.org/10.1007/BF00255763
- Liver Disease
- Clinical Pharmacology
- Drug Clearance
- Plasma Decay
- Marked Liver